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Abstract
Introduction: Critically ill chronic obstructive pulmonary disease (COPD) patients are at particular risk of invasive
pulmonary aspergillosis (IPA). Our aims were to determine whether bronchoalveolar lavage fluid (BALF)
galactomannan (GM) has a higher sensitivity and specificity than serum GM or lower respiratory tract (LRT) sample
culture. Furthermore, we aimed to investigate what the optimal cut-off value would be for BALF GM.
Methods: In this prospective single-center study, BALF and serum samples were collected from critically ill COPD
patients on the first day of their intensive care unit admission.
Results: Of 50 critically ill COPD patients admitted, BALF and serum samples were collected in 34 patients.
According to the receiver operating characteristics (ROC) curve, an optical density (OD) ratio of 0.8 was chosen as
the cut-off value for GM in BALF. Compared to serum GM and LRT Aspergillus isolation, BALF GM yield a better
sensitivity, specificity, positive and negative predictive values of 88.9%, 100%, 100% and 94.4%, respectively. Areas
under the ROC curve were 0.912 (95%CI, 0.733 to 0.985) for BALF GM, and 0.879 (95%CI, 0.691 to 0.972) for serum
GM results from the first day of ICU admission. Pairwise comparison of ROC curves showed P = 0.738. The OD ratio
of BALF GM in IPA patients were significantly higher than those of non-IPA patients (2.88 ± 2.09 versus 0.49 ± 0.19,
P = 0.009), and the OD ratio of BALF GM was significantly higher than serum GM in IPA patients (2.88 ± 2.09 versus
0.87 ± 0.47, P = 0.023). Positive BALF GM was seen earlier than LRT secretion culture (1 day versus 3.8 days).
Conclusions: Compared to serum GM and LRT Aspergillus isolation, BALF GM seems to have a better sensitivity in
the diagnosis of IPA in critically ill COPD patients. The ROC curve suggests a possible cut-off value of 0.8 for GM
from BALF specimens in critically ill COPD patients.
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Introduction
Invasive pulmonary aspergillosis (IPA) is an important
cause of mortality in imunocompromised populations,
such as hematological and solid-organ transplant
patients. In recent years, chronic obstructive pulmonary
disease (COPD) patients, especially those who are criti-
cally ill and are admitted to an ICU, are being increas-
ingly recognized as belonging to a population at
particular risk of IPA. Timely diagnosis of IPA in this
population is challenging due to a lack of specific signs
and symptoms, which contributes to a high mortality of
67% to 100% [1-11].
The Platelia Aspergillus enzyme immunoassay has
being used internationally to detect serum and bronch-
oalveolar lavage fluid (BALF) galactomannan (GM) for
early diagnosis of IPA. In the immunocompromised
population with IPA, serum and BALF GM has been
evaluated extensively [12-15], and is proposed by the
European Organization for Research and Treatment of
Cancer/Mycoses Study Group (EORTC/MSG) Consen-
sus Group as one of the mycological criteria in the
probable IPA diagnosis for this population [16].
The value of serum GM in COPD has been investi-
gated in several studies [9,10,17]. As opposed to immu-
nocompromised populations, these studies demonstrated
a lower sensitivity of only about 30% to 58% in COPD.
The low sensitivity of the galactomannan determination
in serum samples from non-neutropenic patients may
be a consequence of two factors: the clearance of GM
by circulating neutrophils and the less angioinvasive
forms of Aspergillus infection in these patients that
impair the access of GM to the blood stream [18-20].
The sensitivity of BALF GM may be higher than that
from serum because of the high fungal burden in the
bronchial tree of patients with IPA. BALF GM has been
evaluated extensively in neutropenic patients with high
sensitivity. However, data on BALF GM for IPA diagno-
sis in critically ill COPD patients are limited [21] and,
so far, no cut-off value for BALF GM has been estab-
lished for the diagnosis of IPA in this population. The
aim of this prospective single center study is to deter-
mine whether BALF GM has a higher sensitivity and
specificity than serum GM or lower respiratory tract
(LRT) culture. Furthermore, we aimed to investigate
what the optimal cut-off value would be for BALF GM.
Materials and methods
Study population and data collection
In our study, all of the patients were admitted to a
respiratory intensive care unit (RICU) because of respira-
tory failure from February 2009 to December 2009.
These patients were older than 18 years and had been
diagnosed with severe COPD, stage III or IV according to
the Global Initiative for Chronic Obstructive Lung
Disease (GOLD). Patients were excluded for: (i) concur-
rent solid organ tumor; (ii) concurrent hematological sys-
tem diseases; (iii) organ transplantation; (iv) long-term
use of glucocorticoids for reasons other than COPD; and
(v) receiving radiation therapy or immunosuppressive
drugs.
The following information was stored in a data file:
patients’ characteristics, including age, sex, medical his-
tory, reasons for ICU admission; the risk factors for IPA,
including the use of immunosuppressive drugs (steroids
and others), antibiotics and their nutrition [8,22-24]; the
presence of recent exacerbation of dyspnea and rales,
standard ICU laboratory and microbiology findings; and
outcome and cause of death. Beijing Chao-yang Hostipi-
tal IRB approved this study and informed consent was
requested from patients or their next of kin before they
were included in the study.
Collection and processing of clinical samples
BALF and serum sample collection for GM detection was
done on the first day after patients’ admission if feasible,
depending on the patients’ situations.
Fiberoptic bronchoscopy with bronchoalveolar lavage
(20 ml for three times) was performed by experienced
doctors, if feasible. The sampling area was selected based
on the infiltration location on a chest radiograph. If there
were no apparent lesions, the bronchoscope would be
wedged into a segmental airway of the right middle lobe.
Lavage samples were submitted for direct microscopic
examination and microbiological culture. A vortex was
done for the remaining pooled BALF and the supernatant
was stored for GM detection. Five milliliter serum was
collected with a non-anticoagulation tube and was pro-
cessed the same way as BALF for the detection of
galactomannan.
A sandwich ELISA assay for GM detection (Platelia
Aspergillus; Sanofi Diagnostics Pasteur, Marnes-La-
Coquette, France) was performed according to the manu-
facturer’s instructions. An optical density (OD) ratio of
0.5 or greater for serum GM was considered positive [4].
LRT samples (including sputum, endotracheal aspira-
tion) of all patients included in this study were taken once
a day for the first three days of their ICU stay. LRT sam-
ples were collected again once per week if the patient
remained in the ICU for more than seven days. All LRT
specimens and BALF samples were cultured on conven-
tional media, including sheep-blood agar and chocolate
agar. At the same time, all LRT specimens were cultured
on Sabouraud dextrose agar. Samples and specimens were
incubated at 25°C and 37°C, respectively, for 7 to 14 days.
When spore growth was suboptimal on the routine media,
LRT samples were further cultured on potato dextrose
agar for a better conidial production. Aspergillus isolates
were identified by using standard morphologic procedures,
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including colony morphology, growth velocity, color, mor-
phology of hyphae, and characteristics of hyphae and
spores under microscopy.
Case definitions
Each of the patients was classified based on the case
definition proposed by Bulpa et al. [4]. Thus, cases were
diagnosed and classified as proven, probable, possible
IPA or Aspergillus colonization, and non-IPA. Proven
cases required histopathological or cytopathological con-
firmation. Probable cases required both host factors
(COPD patient, had recent exacerbation of dyspnea and
suggestive chest imaging, and typically had poor
response to conventional treatment) and microbiological
factors (isolation of Aspergillus in the LRT samples or
two consecutive positive serum GM tests). Possible
cases required host factors, but without microbiological
proof. Colonization was defined as asymptomatic and
isolation of Aspergillus in LRT samples.
Statistical analysis
Patients were divided into IPA (proven, probable and
possible cases) and non-IPA patients (colonization and
control cases). For further analysis, possible and coloni-
zation patients were excluded from IPA and non-IPA
patients. Using this standard, the ability to predict infec-
tion in critically ill COPD patients on the basis of BALF
GM with a different cut-off value (OD ratio = 0.8 and
0.5, respectively), serum GM and LRT Aspergillus isola-
tion was assessed with respect to the sensitivity, specifi-
city, positive predictive value, and negative predictive
value of these tests. Receiver operating characteristics
(ROC) curves were generated and compared between
serum GM and BALF GM to illustrate the performance
of these two methods. The performance of serum GM
on the first day of ICU admission was used in the com-
parison between serum GM and BALF GM. Normally
distributed continuous variables were expressed as mean
± SD and compared with a t test. P values < 0.05 were
considered significant. All analyses were carried out
with the use of SPSS software for Windows (release
11.5).
Results
Patient characteristics and outcomes
From February 2009 to December 2009, in total, 298
patients were admitted to our ICU because of respiratory
failure. Of these patients, 60 COPD patients were
admitted to our ICU and 50 COPD patients who met the
inclusion criteria were enrolled. Sixteen patients did not
need tracheal intubation and invasive mechanical ventila-
tion, and bronchoscopy was not performed and BALF
samples were not collected in these patients. Thirty-four
BALF samples were collected, twenty-one were from
male and 13 were from female patients. According to the
criteria for IPA, the 34 patients with a BALF sample col-
lected were classified as probable (n = 9), possible
(n = 6), colonization (n = 2) and non-IPA (n = 17). Of
the nine probable IPA patients, four patients used a
broad-spectrum antibiotic for more than 20 days and the
other five patients received one for more than seven days.
Despite antifungal treatments after IPA was diagnosed,
all of these nine patients died (Table 1). Two of the six
possible IPA patients died and the other four patients
recovered. Two patients with Aspergillus isolation were
considered as colonization because their conditions were
improved with no pulmonary lesions revealed on their
chest radiography and no antifungal treatment. Fifteen
non-IPA patients survived. The other two non-IPA
patients died of multiple organ failure and respiratory
failure, respectively.
The nine critically ill probable IPA patients with
COPD are described in Table 1. All of the nine probable
IPA patients had progressive dyspnea, eight patients had
a fever over 38°C and six patients still had fever 72
hours after they received broad spectrum {here should
be no blank lines between “spectrum” and “antibiotics"}
antibiotics. Chest pain occurred in only one IPA patient
and no hemoptysis was observed. Congestion and
edema of the bronchial mucosa were observed under
bronchoscopy, and infiltrates were seen on the chest
radiography in all IPA patients. Five patients had a high
resolution computed tomography (HRCT) scan, and
only one patient showed cavity. Bacterial cultures of
BALF or bronchial secretions showed Acinetobacter
baumanii, Escherichia coli and Burkholderia yabunchi in
four, one and one IPA patients, respectively. Anti-bac-
terial therapy was given to these patients according to
the culture results and the main cause of respiratory
infection was considered to be the Aspergillus species.
BALF GM, serum GM, and LRT sample culture
Levels of BALF and serum GM of IPA patients are
shown in Table 1. Eight IPA patients had an OD ratio
of BALF GM of more than 0.85, while only one IPA
patient had a BALF GM less than 0.5. The BALF GM
levels in IPA patients were significantly higher than in
their serum (OD ratio of 2.88 ± 2.09 versus 0.87 ± 0.47,
P = 0.023). BALF GM levels were significantly higher in
IPA patients compared with non-IPA patients (OD ratio
of 2.88 ± 2.09 versus 0.49 ± 0.19, P = 0.009). Only two
patients received piperacillin/tazobactam treatment
before and during their ICU stay. One patient had a
BALF GM of 0.693, but with a negative serum GM of
0.166. The BALF and serum GM were 0.322 and 0.283
for the other patient. No association was observed
between antibiotic use and GM levels in either serum or
BALF samples.
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The sensitivity, specificity, and the positive and negative
predictive values of BALF GM, serum GM and LRT
Aspergillus isolation for the patients with true infection
(probable cases) and those without infection (non-IPA),
and for all patients (including probable, possible, coloniza-
tion and non-IPA patients) are shown in Table 2 and
Table 3 respectively. Compared to serum GM and LRT
Aspergillus isolation, BALF GM showed a better sensitivity
and negative predictive values, a same specificity and posi-
tive predictive values of 88.9%, 94.4%, 100% and 100% for
probable IPA in critically ill COPD patients, respectively.
However, the confidence intervals of the sensitivity esti-
mates overlap between BALF, serum and LRT.
The ROC curves for BALF and serum GM for the
patients with true infection (probable cases) and those
without infection (non-IPA), and for all patients (includ-
ing probable, possible, colonization and non-IPA
patients) are shown in Figure 1 and 2. The ROC curve
suggested an optimal cut-off value of 0.8 for the OD
ratio of BALF GM. Comparisons of the area under the
curve between BALF and serum were not statistically
significant in either test.
For the 34 patients whose BALF were collected, mor-
tality was significantly higher in patients whose OD
ratios of BALF GM were more than 0.8 than in those
patients whose BALF GM were less than 0.8 (80% ver-
sus 25%, P = 0.002).
The sensitivity of direct microscopy and culture of
LRT specimens were 11% and 67% for probable IPA
and control patients, respectively. In one IPA patient
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APACHE II, Acute Physiology and Chronic Health Evaluation II; BALF, bronchoalveolar lavage fluid; GM, galactomannan, MOF, multiple organ failure; RF, renal
failure; SS, septic shock.
Table 2 Results of BALF and serum GM detection and isolation of Aspergillus from LRT in critically ill COPD patients.
BALF GM ( 95%CI)
(cut-off 0.8)
BALF GM ( 95%CI)
(cut-off 0.5)
Serum GM ( 95%CI)
(cut-off 0.5)
Isolation of Aspergillus from LRT ( 95%CI)
Sensitivity (%) 88.9 (76.8 to 101) 88.9 (76.8 to 101) 77.8 (61.8 to 93.8) 66.7 (48.6 to 84.8)
Specificity (%) 100 (100 to 100) 47.1 (27.9 to 66.3) 100 (100 to 100) 100 (100 to 100)
PPV (%) 100 (100 to 100) 47.1 (27.9 to 66.3) 100 (100 to 100) 100 (100 to 100)
NPV (%) 94.4 (85.6 to 103.2) 88.9 (76.8 to 101) 89.5 (77.7 to 101.3) 85.0 (71.3 to 98.7)
TCR (%) 96.1 (88.7 to 103.5) 61.5 (42.8 to 80.2) 92.3 (82.1 to 102.5) 88.5 (76.2 to 100.8)
For probable IPA and control patients (n = 26).
BALF, bronchoalveolar lavage fluid; COPD, chronic obstructive pulmonary disease; GM, galactomannan; IPA, invasive pulmonary aspergillosis; LRT, lower
respiratory tract; NPV, negative predictive value; PPV, positive predictive value; TCR, total consistent rate.
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(Table 1 case 1), BALF GM showed positive three days
before his serum GM turned positive. Positive BALF
GM emerged significantly earlier than LRT sample cul-
ture (1 day versus 3.8 days).
Discussion
Our study revealed that, compared to LRT Aspergillus
isolation and serum GM, BALF GM might have a bet-
ter sensitivity and a same specificity, and may improve
the diagnosis of IPA in critically ill COPD patients.
When critically ill COPD patients admitted to ICU,
are intubated and mechanically ventilated, LRT sam-
ples can be more easily collected. However, the sensi-
tivity of Aspergillus culture and direct microscopic
examination was only about 40% [25]. In addition,
Aspergillus culture takes at least 24 to 72 hours and
may delay the diagnosis of IPA. In our study, the sensi-
tivity of direct microscopy and culture of LRT speci-
mens were 11% and 67%, respectively, which is lower
than serum and BALF GM.
Serum GM has been evaluated extensively in neutro-
penic patients with a sensitivity of 71% and a specificity
of 89%. Furthermore, positive serum GM is proposed as
a criterion for probable IPA by the EORTC/MSG Con-
sensus Group [12-14,16]. However, for non-neutropenic
patients, including COPD patients, some reports sug-
gested a low sensitivity of serum GM for IPA [18,19].
Besides, several factors may cause false-positive results
in serum GM determination, such as intravenous use of
piperacillin/tazobactam, amoxicillin/clavulanic acid,
Table 3 BALF, serum GM and Aspergillus isolation from LRT.
BALF GM ( 95%CI)
(cut-off 0.8)
BALF GM ( 95%CI)
(cut-off 0.5)
Serum GM ( 95%CI)
(cut-off 0.5)
Isolation of Aspergillus from LRT ( 95%CI)
Sensitivity (%) 66.7 (48.6 to 84.8) 73.3 (56.3 to 90.3) 53.3 (34.1 to 72.5) 46.7 (27.5 to 65.9)
Specificity (%) 100 (100 to 100) 52.6 (33.4 to 71.8) 100 (100 to 100) 89.5 (77.7 to 101.3)
PPV (%) 100 (100 to 100) 55.0 (35.9 to 74.1) 100 (100 to 100) 77.8 (61.8 to 93.8)
NPV (%) 79.1 (63.5 to 94.7) 71.4 (54.0 to 88.8) 73.0 (55.9 to 90.1) 68.0 (50.1 to 85.9)
TCR (%) 85.3 (71.7 to 98.9) 61.8 (43.1 to 80.5) 79.4 (63.9 to 94.9) 70.6 (53.1 to 88.1)
For probable, possible IPA, colonization and control patients (n = 34).
BALF, bronchoalveolar lavage fluid; CI, confidence interval; COPD, chronic obstructive pulmonary disease; GM, galactomannan; IPA, invasive pulmonary
aspergillosis; LRT, lower respiratory tract; NPV, negative predictive value; PPV, positive predictive value; TCR, total consistent rate.
Figure 1 For probable IPA and control patients (n = 26). Receiver operating characteristics (ROC) curve for galactomannan (GM) detection in
bronchoalveolar lavage fluid (BALF) and serum graphing sensitivity (true positive results) versus 1-specificity (true negative results) using BALF
GM and serum GM to define positivity. Areas under the ROC curve were 0.912 (95%CI, 0.733 to 0.985) for BALF GM and 0.879 (95%CI, 0.691 to
0.972) for serum GM result on the first day of ICU admission. Pairwise comparison of ROC curves showed P = 0.738. CI, confidence interval.
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albumin, and the contamination of water and food
[26,27].
In COPD patients, because the structures and defense
functions of the airways and lung parenchyma are
damaged by underlying respiratory diseases, Aspergillus
may colonize in these sites. During the early period of
invasive aspergillosis, infection may be limited to the
tracheobronchial region, presenting as Aspergillus tra-
cheal-bronchitis. With corticosteroids and broad-spec-
trum antibiotics therapy, the infection could spread to
the distal airways and lung parenchyma, presenting as
IPA [10]. During the later stage, hyphae invade into the
blood vessels, and galacotomannan is released into the
circulation. GM from BALF may be increased earlier
than that from serum because of the high fungal burden
in the bronchial region in the early stage of IPA. A pre-
vious study indicated that in patients admitted to ICU,
including critically ill COPD patients, when using a cut-
off index of 0.5, the sensitivity and specificity of BALF
GM was 88% and 87%, respectively, while the sensitivity
of serum GM was only 42% [28]. Our study suggests
that, on the first day of ICU admission, the average level
of BALF GM was significantly higher than that of serum
GM in COPD patients with IPA.
One of the main problems encountered in GM assay
in BALF is that no standardized procedure for BALF
collection is defined at present. In our study, we per-
formed the bronchoalveolar lavage procedure used in a
previous study for ICU patients [28]. The BALF was
obtained after three successive injections of 20 mL of
saline. This volume could be considered as a low
volume, especially for the COPD patients. Due to their
obstructive ventilatory disorder, removal of injected
fluid could be frequently ineffective. However, the
volume retrieved in our patients ranged from 24 mL to
42 mL, which was approximately 50% of the volume of
the injection. The variation of the volume is important
because the amount of fluid injected and retrieved may
influence the final concentration of GM. Independent of
this dilution factor, it is empirically known that a ‘small’
lavage explores the alveoli less deeply than a ‘large’ one.
Therefore, this is a point likely to introduce discrepan-
cies in studies focusing on this topic, and which volume
and number of times the injection should be performed
needs to be standardized in future studies.
The EORTC/MSG criteria for IPA were developed for
patients with malignant disease and recipients of allo-
geneic hematopoietic stem cell and solid-organ trans-
plants [16]. Due to the absence of data, the criteria do
not apply to non-cancer populations. In 2007, Bulpa et
al. proposed their definitions of IPA, specifically for
COPD patients and isolation of Aspergillus [4] based on
Figure 2 For probable IPA, possible IPA, colonization and control patients (n = 34). Receiver operating characteristics (ROC) curve for
galactomannan (GM) detection in bronchoalveolar lavage fluid (BALF) and serum graphing sensitivity (true positive results) versus 1-specificity
(true negative results) using BALF GM and serum GM to define positivity. Areas under the ROC curve were 0.830 (95%CI, 0.662 to 0.936) for BALF
GM and 0.784 (95%CI, 0.610 to 0.906) for serum GM result on the first day of ICU admission. Pairwise comparison of ROC curves showed P=
0.604. CI, confidence interval.
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several case reports. The diagnoses for 36 patients (64%)
were classified as proven in their study, which validated
their criteria. Their criteria have been used as diagnostic
criteria in several recent reports [17,29,30], and may be
more appropriate for IPA in our study with the COPD
population.
The frequency of IPA in this study was 15% (9/60),
and higher than that in the recent paper by Aquino et
al. on a similar patient population [31]. The incidence
of IPA in COPD populations from whom the Aspergillus
was recovered in culture was 16.1% to 22.1% [17]. This
incidence was even higher, at 37%, for those COPD
patients whose specimens yielded Aspergillus and who
required admission to the ICU [17].
The current study has several limitations. First, since
the collection and processing of BALF samples has not
yet been standardized, we followed the method used in
a previous study [28]. Second is the relatively small sam-
ple size. Third, serum GM and LRT Aspergillus isolation
were included in the criteria to define IPA. This may
have caused ‘incorporation bias’. By incorporating the
test(s) under evaluation in the reference standard (the
IPA criteria), the sensitivity and specificity of these tests
may look higher than they are in reality. Finally,
although all probable IPA patients enrolled were non-
survivors, post-mortem examinations were rejected by
the family members of these patients and were not per-
formed for a definitive diagnosis of invasive aspergillosis.
Conclusions
Compared to serum GM and LRT Aspergillus isolation,
BALF GM appears to have a higher sensitivity in the
early diagnosis of IPA in critically ill COPD patients.
The ROC curve suggests a possible cut off value of 0.8
for BALF specimens. Evidence-based prospective studies
are needed for further evaluation of the usefulness and
standardization of the procedure of BALF GM in criti-
cally ill COPD patients.
Key messages
• Compared to serum GM and LRT culture, BALF
GM appears to have an increased sensitivity in the
diagnosis of IPA in critically ill COPD patients.
• A possible cut off value of OD ratio of 0.8 for GM
from BALF specimens may be suggested for the
diagnosis of IPA in critically ill COPD patients.
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